Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.17
NYSE:DVA's Cash to Debt is ranked lower than
59% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. NYSE:DVA: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:DVA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.12 Max: 5.2
Current: 0.17
0
5.2
Equity to Asset 0.26
NYSE:DVA's Equity to Asset is ranked lower than
81% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NYSE:DVA: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:DVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.03  Med: 0.25 Max: 0.62
Current: 0.26
0.03
0.62
Interest Coverage 4.25
NYSE:DVA's Interest Coverage is ranked lower than
68% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 7.01 vs. NYSE:DVA: 4.25 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: N/A
Current: 4.25
F-Score: 7
Z-Score: 2.09
M-Score: -2.70
WACC vs ROIC
6.85%
8.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 12.07
NYSE:DVA's Operating margin (%) is ranked higher than
65% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.81 vs. NYSE:DVA: 12.07 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:DVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 16.38
Current: 12.07
8.49
16.38
Net-margin (%) 4.92
NYSE:DVA's Net-margin (%) is ranked higher than
52% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. NYSE:DVA: 4.92 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:DVA' s Net-margin (%) Range Over the Past 10 Years
Min: 1.96  Med: 6.42 Max: 7.25
Current: 4.92
1.96
7.25
ROE (%) 14.78
NYSE:DVA's ROE (%) is ranked higher than
70% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 9.71 vs. NYSE:DVA: 14.78 )
Ranked among companies with meaningful ROE (%) only.
NYSE:DVA' s ROE (%) Range Over the Past 10 Years
Min: 5.37  Med: 20.55 Max: 27.64
Current: 14.78
5.37
27.64
ROA (%) 3.83
NYSE:DVA's ROA (%) is ranked lower than
51% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. NYSE:DVA: 3.83 )
Ranked among companies with meaningful ROA (%) only.
NYSE:DVA' s ROA (%) Range Over the Past 10 Years
Min: 1.48  Med: 4.86 Max: 5.69
Current: 3.83
1.48
5.69
ROC (Joel Greenblatt) (%) 54.95
NYSE:DVA's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. NYSE:DVA: 54.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:DVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.56  Med: 57.03 Max: 68.47
Current: 54.95
36.56
68.47
Revenue Growth (3Y)(%) 15.10
NYSE:DVA's Revenue Growth (3Y)(%) is ranked higher than
76% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. NYSE:DVA: 15.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:DVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 15.1 Max: 39.8
Current: 15.1
4.8
39.8
EBITDA Growth (3Y)(%) -0.60
NYSE:DVA's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 7.40 vs. NYSE:DVA: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:DVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.3  Med: 15 Max: 98.2
Current: -0.6
-25.3
98.2
EPS Growth (3Y)(%) -23.00
NYSE:DVA's EPS Growth (3Y)(%) is ranked lower than
88% of the 133 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. NYSE:DVA: -23.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:DVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: -23
-29
125.5
» NYSE:DVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

DVA Guru Trades in Q4 2015

Paul Tudor Jones 20,656 sh (New)
Ray Dalio 31,945 sh (New)
Joel Greenblatt 302,502 sh (+525.25%)
Jim Simons 924,100 sh (+126.16%)
Manning & Napier Advisors, Inc 1,887,295 sh (+34.27%)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Steve Mandel Sold Out
Mario Gabelli 39,963 sh (-4.31%)
Arnold Van Den Berg 268,133 sh (-6.22%)
Alan Fournier 1,286,097 sh (-35.69%)
» More
Q1 2016

DVA Guru Trades in Q1 2016

Andreas Halvorsen 1,744,519 sh (New)
Joel Greenblatt 513,100 sh (+69.62%)
Arnold Van Den Berg 328,908 sh (+22.67%)
Jim Simons 1,091,500 sh (+18.11%)
Mario Gabelli 41,563 sh (+4.00%)
Manning & Napier Advisors, Inc 1,911,305 sh (+1.27%)
Warren Buffett 38,565,570 sh (unchged)
Paul Tudor Jones Sold Out
Alan Fournier Sold Out
Ray Dalio 6,600 sh (-79.34%)
» More
Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:NYSE:UHS, OTCPK:RMSYF, OTCPK:SKHCY, NYSE:MD, NAS:WOOF, NYSE:HLS, NAS:AMSG, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:SEM, NYSE:THC, NYSE:AMN, NAS:AMED, NAS:PAHC, NAS:HWAY, NAS:LHCG, NAS:SGRY » details
Traded in other countries:TRL.Germany,
DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services mainly in dialysis centers and in contracted hospitals across the United States. It also operates other ancillary services and strategic initiatives.

DaVita Inc, formerly DaVita HealthCare Partners Inc was incorporated as a Delaware corporation in 1994. It is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease, or ESRD. The Company also provides administrative and management support services to a medical services joint venture in which the Company owns a 50% interests. As of December 31, 2014, it provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. It also provides acute inpatient dialysis services in approximately 1,000 hospitals and related laboratory services throughout the United States. The United States dialysis and related lab services business. Home-based dialysis services consist of providing equipment and supplies, training, patient monitoring, on-call support services and follow-up assistance to patients who prefer and are able to receive either peritoneal dialysis or hemodialysis treatments in their homes. It provides hospital inpatient hemodialysis services are required for patients with acute kidney failure resulting from trauma, patients in early stages of ESRD and ESRD patients who require hospitalization for other reasons. It owns two separately incorporated, licensed, clinical laboratories, both located in Florida, specializing in ESRD patient testing. These specialized laboratories provide routine laboratory tests covered by the Medicare composite payment rate for dialysis and other physician-prescribed laboratory tests for ESRD patients. The Company's laboratories provide these tests predominantly for its own ESRD patients throughout the United States. It currently operates or provides management and administrative services to 29 outpatient dialysis centers, in which it either owns a non-controlling interest, or is wholly-owned by third parties, under management and administrative services agreements. It continues to face increased competition in the dialysis industry from large and medium-sized providers which compete directly with it for acquisition targets as well as for individual patients.

Top Ranked Articles about DaVita Inc

Arnold Van Den Berg Sells Coca-Cola, DaVita Largest trades by the investor in the second quarter
Arnold Van Den Berg (Trades, Portfolio) is a value investor and considers himself a student of Benjamin Graham. His investment research seeks to determine the appraised value of a company, often referred to as intrinsic value. Read more...
Low P/S Ratios for DaVita, ConAgra Foods Gurus have been snapping up these stocks
According to GuruFocus' All-in-One Screener, the following are companies with market caps above $5 billion that are trading with low P/S ratios. Read more...
Weekly CEO Sells Highlights Insiders sell INC Research Holdings, DaVita HealthCare Partners, TE Connectivity, Ruckus Wireless
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: INC Research Holdings Inc. (NASDAQ:INCR), DaVita HealthCare Partners Inc. (NYSE:DVA), TE Connectivity Ltd. (NYSE:TEL) and Ruckus Wireless Inc. (NYSE:RKUS). Read more...
Steve Mandel Sells Health Care Stakes Guru sells holdings in Allergan and DaVita HealthCare Partners
Steve Mandel (Trades, Portfolio), founder of Lone Pine Capital, sold out two health care stakes in the fourth quarter. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.60
DVA's P/E(ttm) is ranked higher than
68% of the 245 Companies
in the Global Medical Care industry.

( Industry Median: 25.71 vs. DVA: 18.60 )
Ranked among companies with meaningful P/E(ttm) only.
DVA' s P/E(ttm) Range Over the Past 10 Years
Min: 11.6  Med: 19.04 Max: 58.72
Current: 18.6
11.6
58.72
Forward P/E 15.41
DVA's Forward P/E is ranked higher than
66% of the 91 Companies
in the Global Medical Care industry.

( Industry Median: 18.15 vs. DVA: 15.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.60
DVA's PE(NRI) is ranked higher than
71% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 25.75 vs. DVA: 18.60 )
Ranked among companies with meaningful PE(NRI) only.
DVA' s PE(NRI) Range Over the Past 10 Years
Min: 11.57  Med: 19.04 Max: 58.72
Current: 18.6
11.57
58.72
Price/Owner Earnings (ttm) 25.18
DVA's Price/Owner Earnings (ttm) is ranked higher than
54% of the 91 Companies
in the Global Medical Care industry.

( Industry Median: 27.32 vs. DVA: 25.18 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.74  Med: 16.86 Max: 1003.06
Current: 25.18
9.74
1003.06
P/B 2.65
DVA's P/B is ranked higher than
50% of the 284 Companies
in the Global Medical Care industry.

( Industry Median: 2.59 vs. DVA: 2.65 )
Ranked among companies with meaningful P/B only.
DVA' s P/B Range Over the Past 10 Years
Min: 2.25  Med: 3.26 Max: 7.09
Current: 2.65
2.25
7.09
P/S 0.92
DVA's P/S is ranked higher than
68% of the 281 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. DVA: 0.92 )
Ranked among companies with meaningful P/S only.
DVA' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.17 Max: 2.07
Current: 0.92
0.77
2.07
PFCF 12.24
DVA's PFCF is ranked higher than
82% of the 131 Companies
in the Global Medical Care industry.

( Industry Median: 23.98 vs. DVA: 12.24 )
Ranked among companies with meaningful PFCF only.
DVA' s PFCF Range Over the Past 10 Years
Min: 7.52  Med: 16.72 Max: 42.52
Current: 12.24
7.52
42.52
POCF 6.98
DVA's POCF is ranked higher than
83% of the 191 Companies
in the Global Medical Care industry.

( Industry Median: 14.06 vs. DVA: 6.98 )
Ranked among companies with meaningful POCF only.
DVA' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 9.33 Max: 17.87
Current: 6.98
5.22
17.87
EV-to-EBIT 11.49
DVA's EV-to-EBIT is ranked higher than
83% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 19.73 vs. DVA: 11.49 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 12.3 Max: 21.5
Current: 11.49
8.5
21.5
EV-to-EBITDA 8.30
DVA's EV-to-EBITDA is ranked higher than
86% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 14.47 vs. DVA: 8.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 9.8 Max: 17.1
Current: 8.3
6.8
17.1
PEG 1.93
DVA's PEG is ranked higher than
65% of the 81 Companies
in the Global Medical Care industry.

( Industry Median: 2.66 vs. DVA: 1.93 )
Ranked among companies with meaningful PEG only.
DVA' s PEG Range Over the Past 10 Years
Min: 0.41  Med: 1.48 Max: 5.68
Current: 1.93
0.41
5.68
Shiller P/E 25.02
DVA's Shiller P/E is ranked higher than
62% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. DVA: 25.02 )
Ranked among companies with meaningful Shiller P/E only.
DVA' s Shiller P/E Range Over the Past 10 Years
Min: 19.78  Med: 29.99 Max: 54.81
Current: 25.02
19.78
54.81
Current Ratio 1.61
DVA's Current Ratio is ranked higher than
62% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. DVA: 1.61 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.86 Max: 5.97
Current: 1.61
0.39
5.97
Quick Ratio 1.54
DVA's Quick Ratio is ranked higher than
65% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. DVA: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.79 Max: 5.97
Current: 1.54
0.37
5.97
Days Inventory 6.62
DVA's Days Inventory is ranked higher than
80% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 18.12 vs. DVA: 6.62 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 5.97 Max: 8.61
Current: 6.62
3.72
8.61
Days Sales Outstanding 46.38
DVA's Days Sales Outstanding is ranked lower than
56% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 42.08 vs. DVA: 46.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 62.93 Max: 69.73
Current: 46.38
43.53
69.73
Days Payable 17.38
DVA's Days Payable is ranked lower than
78% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 38.52 vs. DVA: 17.38 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.77  Med: 20.99 Max: 27.1
Current: 17.38
14.77
27.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. DVA: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.6  Med: -0.8 Max: 9.3
Current: 0.2
-22.6
9.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.81
DVA's Price/Projected FCF is ranked higher than
87% of the 115 Companies
in the Global Medical Care industry.

( Industry Median: 1.81 vs. DVA: 0.81 )
Ranked among companies with meaningful Price/Projected FCF only.
DVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.15 Max: 6.25
Current: 0.81
0.79
6.25
Price/DCF (Earnings Based) 1.54
DVA's Price/DCF (Earnings Based) is ranked higher than
56% of the 32 Companies
in the Global Medical Care industry.

( Industry Median: 1.63 vs. DVA: 1.54 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.79
DVA's Price/Median PS Value is ranked higher than
77% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. DVA: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
DVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.02 Max: 2.33
Current: 0.79
0.15
2.33
Price/Peter Lynch Fair Value 2.53
DVA's Price/Peter Lynch Fair Value is ranked lower than
60% of the 57 Companies
in the Global Medical Care industry.

( Industry Median: 1.97 vs. DVA: 2.53 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.27 Max: 8.16
Current: 2.53
0.39
8.16
Earnings Yield (Greenblatt) (%) 8.62
DVA's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 295 Companies
in the Global Medical Care industry.

( Industry Median: 4.17 vs. DVA: 8.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 8.15 Max: 11.8
Current: 8.62
4.7
11.8
Forward Rate of Return (Yacktman) (%) 14.07
DVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 110 Companies
in the Global Medical Care industry.

( Industry Median: 10.28 vs. DVA: 14.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.3  Med: 20.3 Max: 34.6
Current: 14.07
12.3
34.6

More Statistics

Revenue (TTM) (Mil) $14,563
EPS (TTM) $ 3.46
Beta0.97
Short Percentage of Float4.15%
52-Week Range $54.50 - 78.77
Shares Outstanding (Mil)197.40

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 14,738 15,623
EPS ($) 3.80 4.20
EPS w/o NRI ($) 3.80 4.20
EPS Growth Rate
(3Y to 5Y Estimate)
13.16%
Dividends Per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
Are Any of Buffett's Holdings Cheap Enough to Buy? Nov 09 2016 
3 Warren Buffett Stocks Fall to 52-Week Lows Oct 28 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Arnold Van Den Berg's Largest Buys in 1st Quarter Apr 21 2016 
Weekly CEO Sells Highlights Apr 18 2016 
7 High Quality Guru Stocks Apr 11 2016 
Steve Mandel Sells Health Care Stakes Mar 11 2016 
Undervalued, Predictable Companies Include Monsanto and Western Union Mar 10 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 

More From Other Websites
DaVita and Rock Health Announce Partnership to Advance Innovation in Healthcare Nov 29 2016
Humana to Add JSA Medical Group’s New Primary Care Practices Designed Exclusively for Medicare... Nov 28 2016
Has The Time To Buy Davita Inc (DVA) Arrived? Nov 24 2016
ETFs with exposure to DaVita, Inc. : November 22, 2016 Nov 22 2016
DaVita, Inc. breached its 50 day moving average in a Bearish Manner : DVA-US : November 21, 2016 Nov 21 2016
HealthCare Partners Saves $1.6 million in Anthem Blue Cross Enhanced Personal Health Care Program Nov 17 2016
HealthCare Partners Encourages Medicare Beneficiaries to Review Health Plans during Open Enrollment Nov 17 2016
DaVita Clinical Research to Present 12 Abstracts at American Society of Nephrology Kidney Week 2016 Nov 14 2016
Election 2016: Colorado voters embrace open primary elections Nov 09 2016
DAVITA INC. Financials Nov 09 2016
DaVita Supports National Diabetes Month Nov 08 2016
ETF’s with exposure to DaVita, Inc. : November 7, 2016 Nov 07 2016
DaVita, Inc. :DVA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 4, 2016 Nov 04 2016
DaVita (DVA) Q3 Earnings Beat Estimates on Lower Expenses Nov 03 2016
Edited Transcript of DVA earnings conference call or presentation 2-Nov-16 9:00pm GMT Nov 03 2016
DaVita Inc Earnings Call scheduled for 5:00 pm ET today Nov 02 2016
DAVITA INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 02 2016
DaVita HealthCare tops 3Q profit forecasts Nov 02 2016
DaVita HealthCare tops 3Q profit forecasts Nov 02 2016
DaVita Inc. 3rd Quarter 2016 Results Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)